Get the Stockscreener App
33.44
0.79%
-0.235
Exelixis Inc stock is traded at $33.44, with a volume of 556.88K.
It is down -0.79% in the last 24 hours and down -2.35% over the past month.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$33.67
Open:
$33.6
24h Volume:
556.88K
Relative Volume:
0.26
Market Cap:
$9.62B
Revenue:
$2.08B
Net Income/Loss:
$466.92M
P/E Ratio:
21.43
EPS:
1.56
Net Cash Flow:
$404.94M
1W Performance:
+0.77%
1M Performance:
-2.35%
6M Performance:
+25.96%
1Y Performance:
+65.53%
1-Day Range:
$33.10
$33.80
1-Week Range:
$32.44
$33.87
52-Week Range:
$20.02
$37.59
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
33.41 | 9.62B | 2.08B | 466.92M | 404.94M | 1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.30 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.62 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.97 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.75 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Zacks.com featured highlights include Pilgrim's Pride, Exelixis, Synchrony and United Airlines - Yahoo Finance
Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key Metrics - MSN
ILMN: 3 Genomics Stocks Unlocking the Future of Medicine - StockNews.com
(EXEL) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by Robeco Institutional Asset Management B.V. - MarketBeat
Blue Trust Inc. Purchases 8,208 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Smith Group Asset Management LLC Invests $305,000 in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis (EXEL) to Release Quarterly Earnings on Tuesday - MarketBeat
Exelixis (NASDAQ:EXEL) Stock Price Expected to Rise, UBS Group Analyst Says - MarketBeat
Exelixis's SWOT analysis: cancer drug maker's stock faces patent cliff, pipeline promise - MSN
Exelixis announces results from expansion cohort of phase 1b/2 STELLAR-001 - MSN
Morgan Stanley lifts Exelixis stock rating to Overweight - MSN
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
Exelixis patent discloses USP1 inhibitors for cancer - BioWorld Online
Exelixis's SWOT analysis: cabo strength drives stock amid IP challenges - MSN
Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025 - Business Wire
Is Exelixis a Biotech Stock Worth Adding to Your Portfolio? - Inkl
EXEL: Is Exelixis a Biotech Stock Worth Adding to Your Portfolio? - StockNews.com
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Exelixis's SWOT analysis: cabo strength drives stock amid IP challenges By Investing.com - Investing.com Australia
Exelixis (NASDAQ:EXEL) Given Equal Weight Rating at Stephens - Defense World
Exelixis (NASDAQ:EXEL) Given New $43.00 Price Target at Truist Financial - Defense World
Exelixis (NASDAQ:EXEL) Rating Increased to Overweight at Morgan Stanley - Defense World
Exelixis (NASDAQ:EXEL) Given “Buy” Rating at HC Wainwright - Defense World
Exelixis downgraded by Oppenheimer to perform - MSN
Morgan Stanley lifts Exelixis stock rating to Overweight By Investing.com - Investing.com Canada
Truist raises Exelixis stock target to $43 on Zanza optimism - MSN
Morgan Stanley Upgrades Exelixis (EXEL) - MSN
Stifel maintains hold rating, $30 target on Exelixis stock - MSN
Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform - Yahoo Finance
Exelixis (NASDAQ:EXEL) Price Target Raised to $43.00 - MarketBeat
Exelixis (NASDAQ:EXEL) Receives "Equal Weight" Rating from Stephens - MarketBeat
Truist raises Exelixis stock target to $43 on Zanza optimism By Investing.com - Investing.com UK
H.C. Wainwright maintains $40 target on Exelixis stock - Investing.com India
Exelixis (NASDAQ:EXEL) Upgraded by Morgan Stanley to Overweight Rating - MarketBeat
Exelixis (NASDAQ:EXEL) Receives "Buy" Rating from HC Wainwright - MarketBeat
Exelixis stock holds Market Outperform rating, $41 target - MSN
This Twilio Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
Exelixis, Inc. (NASDAQ:EXEL) Stake Boosted by Nisa Investment Advisors LLC - Defense World
Park Avenue Securities LLC Purchases New Shares in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Nisa Investment Advisors LLC Increases Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
8,301 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by DGS Capital Management LLC - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Exchange Traded Concepts LLC - MarketBeat
UMB Bank n.a. Purchases 553 Shares of Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Exelixis's SWOT analysis: cabozantinib strength, pipeline potential drive stock - MSN
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Exelixis Inc Stock (EXEL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hessekiel Jeffrey | EVP & General Counsel |
Nov 29 '24 |
Sale |
36.67 |
60,000 |
2,200,200 |
486,059 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):